Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 4 Date: 13 Feb 2023
Reviewer's report:
Thank you very much for giving me the opportunity to review the "revised" manuscript.
I really think the work addresses an important topic and I appreciate the revised version.
I still think that data on disease history (duration, activity, risk factors) are important to define the
real possibility of comparison between different populations. Therefore, the conclusions should
still refer to this possible bias.
Conflict interest should be clearly stated.
Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 4 Date: 13 Feb 2023
Reviewer's report:
Thank you very much for giving me the opportunity to review the "revised" manuscript.
I really think the work addresses an important topic and I appreciate the revised version.
I still think that data on disease history (duration, activity, risk factors) are important to define the
real possibility of comparison between different populations. Therefore, the conclusions should
still refer to this possible bias.
Conflict interest should be clearly stated.
Please review this paper.
user
Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 4 Date: 13 Feb 2023
Reviewer's report:
Thank you very much for giving me the opportunity to review the "revised" manuscript.
I really think the work addresses an important topic and I appreciate the revised version.
I still think that data on disease history (duration, activity, risk factors) are important to define the
real possibility of comparison between different populations. Therefore, the conclusions should
still refer to this possible bias.
Conflict interest should be clearly stated.
assistant